An estimated 5.7 million Americans 65 and older are currently living with Alzheimer's disease. That number could nearly triple by 2050. Among the top ten causes of death in the U.S., Alzheimer's is the only one that cannot be prevented, cured or slowed.
Still, researchers are hopeful they can unlock the mysteries behind Alzheimer's. The AHEAD Study, funded by the National Institutes of Health, is testing an investigational treatment aimed at delaying memory decline in people up to 20 years before the onset of Alzheimer's symptoms to determine whether intervening ahead of symptoms may prevent future memory loss and dementia.
Individuals between the ages 55-80 who are not currently dealing with memory issues are sought to join the AHEAD Study by participating or volunteering at more than 70 sites across the U.S. and Canada, including Dallas-Fort Worth. To learn more and find out if you are eligible, visit AHEADstudy.org.
KRLD's Chris Sommer discussed the study with Dr. Paul Aisen, Professor of Neurology and Director of the Alzheimer's Therapeutic Research Institute at the Univ. of Southern California.